Fulgent Genetics
360Dx Index Follows Larger Market Trends, Drops 4 Percent in November
Of the 29 companies in the index, 10 saw increases in their stock prices, while 19 saw declines.
Fulgent Genetics Q3 Revenues More Than Double; Firm Raises '21 Guidance
The firm's number of billable tests doubled over the prior-year period while its core revenues, excluding COVID-19 testing, grew fourfold.
In Brief This Week: PerkinElmer, Chembio, Becton Dickinson, Fulgent Genetics, and More
News items for the in vitro diagnostic industry for the week of Sept. 20, 2021.
The firm is investing its COVID testing revenues to expand its oncology offerings through acquisitions and partnerships.
Fulgent Genetics Revenues Increase Nearly Ninefold as Firm Makes Acquisition, Cancer Testing Deal
Fulgent announced that it has acquired CSI Laboratories and that it will partner with Helio Health to commercialize early cancer detection tests.
Mar 4, 2021
Fulgent Genetics Q4 Revenues Skyrocket
Nov 24, 2020
BTIG Downgrades Fulgent Genetics from Buy to Neutral
Sep 15, 2020